title: Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells.
abstract: Recently the use of peptides in bee venom (PBV) for cancer therapy has attracted considerable attention. However, PBV's extensive use is prohibited by its intense hemolytic activity. In this study, the sterically stabilized liposomal PBV (PBV-SL) was prepared using soybean phosphatidylcholine, cholesterol, and cholesterol-PEG-COOH. The humanized antihepatoma disulfide-stabilized Fv (hdsFv25) was reengineered, expressed, and coupled to sterically stabilized liposomes using the N-hydroxysuccinimide ester method. The hdsFv25-immunoliposomes (SIL [hdscFv25]) were immunoreactive as determined by ELISA assay. PBV-SIL [hdscFv25] can kill SMMC-7721 cells in vitro with higher efficiency than nontargeted liposomes. PBV-SIL [hdsFv25] displayed high antitumor activity and resulted in a significant reduction in tumor size compared to nontargeted liposomes and PBV. These results indicated that this strategy should be applicable to applicable in the treatment of other cancers.
authors.affiliation: School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang, Liaoning Province, 110016, RP China.
authors.forename: Haiyang
authors.initials: H
authors.lastname: Hu
authors.forename: Dawei
authors.initials: D
authors.lastname: Chen
authors.forename: Yanfang
authors.initials: Y
authors.lastname: Liu
authors.forename: Yihui
authors.initials: Y
authors.lastname: Deng
authors.forename: Shoujing
authors.initials: S
authors.lastname: Yang
authors.forename: Mingxi
authors.initials: M
authors.lastname: Qiao
authors.forename: Jun
authors.initials: J
authors.lastname: Zhao
authors.forename: Xiuli
authors.initials: X
authors.lastname: Zhao
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001514:Bee Venoms / Q000008:administration & dosage* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology; D045744:Cell Line, Tumor; D004220:Disulfides; D006367:HeLa Cells; D006801:Humans; D007128:Immunoglobulin Fragments / Q000008:administration & dosage* / Q000627:therapeutic use; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D001514:Bee Venoms; D004220:Disulfides; D007128:Immunoglobulin Fragments; D008081:Liposomes